|
For the first time in history, we have the potential to significantly reduce the incidence of a female cancer – cervical cancer – through the addition of vaccination to existing screening programs. This opportunity is certainly a great step forward in women’s health and highlights the need for the public health community to work together to ensure access to vaccination, along with screening, for women in the United States. Significant barriers must be addressed to ensure that adult women who may benefit from cervical cancer vaccination and screening have access.
Consequently, the Partnership to End Cervical Cancer – a unique collaboration of nearly 40 leading consumer, professional and policy organizations, public health groups, healthcare professionals and industry – has formed to create a new standard of preventive healthcare for women that includes screening and vaccination to prevent cervical cancer. The mission of the Partnership is:
To ensure the inclusion of vaccination to prevent cervical cancer, along with screening, as part of routine preventive healthcare for all women in the United States.
The Partnership is focused on addressing four major barriers impeding women’s access to cervical cancer vaccination and screening in the United States to achieve its mission by:
The Partnership will work collectively to educate public health decision-makers, healthcare professionals and the general public about oncogenic (cancer-causing) human papillomavirus (HPV) and its role in the development of cervical cancer, as well as educate public health decision-makers on the value of universal access for women to screening and vaccination that prevents cervical cancer.
This Web site is part of the Partnership to End Cervical Cancer. GlaxoSmithKline has provided funding and other support for the Partnership to End Cervical Cancer and members of the Partnership.
|
